332 related articles for article (PubMed ID: 29535383)
1. A LATS biosensor screen identifies VEGFR as a regulator of the Hippo pathway in angiogenesis.
Azad T; Janse van Rensburg HJ; Lightbody ED; Neveu B; Champagne A; Ghaffari A; Kay VR; Hao Y; Shen H; Yeung B; Croy BA; Guan KL; Pouliot F; Zhang J; Nicol CJB; Yang X
Nat Commun; 2018 Mar; 9(1):1061. PubMed ID: 29535383
[TBL] [Abstract][Full Text] [Related]
2. A kinome-wide screen using a NanoLuc LATS luminescent biosensor identifies ALK as a novel regulator of the Hippo pathway in tumorigenesis and immune evasion.
Nouri K; Azad T; Lightbody E; Khanal P; Nicol CJ; Yang X
FASEB J; 2019 Nov; 33(11):12487-12499. PubMed ID: 31431076
[TBL] [Abstract][Full Text] [Related]
3. The Hippo pathway effector proteins YAP and TAZ have both distinct and overlapping functions in the cell.
Plouffe SW; Lin KC; Moore JL; Tan FE; Ma S; Ye Z; Qiu Y; Ren B; Guan KL
J Biol Chem; 2018 Jul; 293(28):11230-11240. PubMed ID: 29802201
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Hippo pathway by mitogenic growth factors via phosphoinositide 3-kinase and phosphoinositide-dependent kinase-1.
Fan R; Kim NG; Gumbiner BM
Proc Natl Acad Sci U S A; 2013 Feb; 110(7):2569-74. PubMed ID: 23359693
[TBL] [Abstract][Full Text] [Related]
5. Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor (LATS) Biosensor.
Azad T; Nouri K; Janse van Rensburg HJ; Hao Y; Yang X
J Vis Exp; 2018 Sep; (139):. PubMed ID: 30272653
[TBL] [Abstract][Full Text] [Related]
6. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
7. A gain-of-functional screen identifies the Hippo pathway as a central mediator of receptor tyrosine kinases during tumorigenesis.
Azad T; Nouri K; Janse van Rensburg HJ; Maritan SM; Wu L; Hao Y; Montminy T; Yu J; Khanal P; Mulligan LM; Yang X
Oncogene; 2020 Jan; 39(2):334-355. PubMed ID: 31477837
[TBL] [Abstract][Full Text] [Related]
8. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
9. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
[TBL] [Abstract][Full Text] [Related]
10. A feed forward loop enforces YAP/TAZ signaling during tumorigenesis.
Gill MK; Christova T; Zhang YY; Gregorieff A; Zhang L; Narimatsu M; Song S; Xiong S; Couzens AL; Tong J; Krieger JR; Moran MF; Zlotta AR; van der Kwast TH; Gingras AC; Sicheri F; Wrana JL; Attisano L
Nat Commun; 2018 Aug; 9(1):3510. PubMed ID: 30158528
[TBL] [Abstract][Full Text] [Related]
11. The Hippo pathway is controlled by Angiotensin II signaling and its reactivation induces apoptosis in podocytes.
Wennmann DO; Vollenbröker B; Eckart AK; Bonse J; Erdmann F; Wolters DA; Schenk LK; Schulze U; Kremerskothen J; Weide T; Pavenstädt H
Cell Death Dis; 2014 Nov; 5(11):e1519. PubMed ID: 25393475
[TBL] [Abstract][Full Text] [Related]
12.
Kim E; Kang JG; Kang MJ; Park JH; Kim YJ; Kweon TH; Lee HW; Jho EH; Lee YH; Kim SI; Yi EC; Park HW; Yang WH; Cho JW
Proc Natl Acad Sci U S A; 2020 Jun; 117(25):14259-14269. PubMed ID: 32513743
[TBL] [Abstract][Full Text] [Related]
13. KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases.
Xiao L; Chen Y; Ji M; Dong J
J Biol Chem; 2011 Mar; 286(10):7788-7796. PubMed ID: 21233212
[TBL] [Abstract][Full Text] [Related]
14. Heat stress activates YAP/TAZ to induce the heat shock transcriptome.
Luo M; Meng Z; Moroishi T; Lin KC; Shen G; Mo F; Shao B; Wei X; Zhang P; Wei Y; Guan KL
Nat Cell Biol; 2020 Dec; 22(12):1447-1459. PubMed ID: 33199845
[TBL] [Abstract][Full Text] [Related]
15. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A
Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277
[TBL] [Abstract][Full Text] [Related]
16. Hippo and PI5P4K signaling intersect to control the transcriptional activation of YAP.
Palamiuc L; Johnson JL; Haratipour Z; Loughran RM; Choi WJ; Arora GK; Tieu V; Ly K; Llorente A; Crabtree S; Wong JCY; Ravi A; Wiederhold T; Murad R; Blind RD; Emerling BM
Sci Signal; 2024 May; 17(838):eado6266. PubMed ID: 38805583
[TBL] [Abstract][Full Text] [Related]
17. The polyomavirus middle T-antigen oncogene activates the Hippo pathway tumor suppressor Lats in a Src-dependent manner.
Shanzer M; Ricardo-Lax I; Keshet R; Reuven N; Shaul Y
Oncogene; 2015 Aug; 34(32):4190-8. PubMed ID: 25362852
[TBL] [Abstract][Full Text] [Related]
18. YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer.
Hergovich A
Breast Cancer Res; 2012 Dec; 14(6):326. PubMed ID: 23216692
[TBL] [Abstract][Full Text] [Related]
19. The characterisation of LATS2 kinase regulation in Hippo-YAP signalling.
Hoa L; Kulaberoglu Y; Gundogdu R; Cook D; Mavis M; Gomez M; Gomez V; Hergovich A
Cell Signal; 2016 May; 28(5):488-497. PubMed ID: 26898830
[TBL] [Abstract][Full Text] [Related]
20. Adhesion to fibronectin regulates Hippo signaling via the FAK-Src-PI3K pathway.
Kim NG; Gumbiner BM
J Cell Biol; 2015 Aug; 210(3):503-15. PubMed ID: 26216901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
